Cingulate Inc. (NASDAQ:CINGW) Sees Significant Drop in Short Interest

Cingulate Inc. (NASDAQ:CINGW) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 402 shares, a decrease of 96.3% from the May 31st total of 10,882 shares. Based on an average trading volume of 13,143 shares, the days-to-cover ratio is presently 0.0 days.

Cingulate Stock Down 14.4%

Shares of NASDAQ CINGW traded down $0.00 during midday trading on Friday, hitting $0.02. 1,777 shares of the company’s stock were exchanged, compared to its average volume of 38,762. The business’s fifty day moving average price is $0.02 and its two-hundred day moving average price is $0.05. Cingulate has a 12-month low of $0.02 and a 12-month high of $0.17.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.